Nova Patents
PL366705A1

Interferon gamma polypeptide variants

Abstract

The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. These novel polypeptide variants all comprise the substitution S99T as compared to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation the naturally occurring N-glycosylation site present at position 97 is significantly beter utilized. Preferably, the variants comprise further modifications, e.g. in order to increase the AUC of such variatns when administered subcutaneously.

Term

Term ended

Projected expiry passed 4 April 2022, 4.5 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

12 priority claims, no other members on record

This recordMember, by publication datePriority claim

Priority claims12

Priority claims
DocumentOfficeKindDate
PA200100579DenmarkA
PA200100579DenmarkA
PA200100714DenmarkA
PA200100714DenmarkA
PA200200198DenmarkA
PA200200198DenmarkA
01200100579–––
01200100714–––
02200200198–––
DKPA200100579–––
DKPA200100714–––
DKPA200200198–––